Home > Insider Trading > Filing (0001079973-25-000521)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1799191	Oncology Institute Inc.	TOI	Services-Offices & Clinics Of Doctors Of Medicine (8011)	843562323

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1891124	Brad Hively	C/O The Oncology Institute Inc. 18000 Studebaker Rd, Suite 800 Cerritos CA 90703		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-03-26	9,056	$1.04	675,809	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Warrant	Acquisiton	2025-03-26	4,528	$0.13	4,528	$1.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,528	2025-03-26	2030-03-26	No	4	P	Direct

Footnotes

Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act.